By Fineline Cube 
China-based CanSino Biologics Inc. (HKG: 6185), a specialist in vaccine development, has announced that it has received approval from Indonesia’s Badan Pengawas Obat dan Makanan (BPOM) to conduct a Phase I clinical study for its inhalable tuberculosis vaccine, which uses an adenovirus type 5 vector.
Vaccine Innovation and Purpose
CanSino’s inhalable tuberculosis booster vaccine is designed to address the insufficient protective effects of the traditional BCG vaccine. It is intended for use in populations that have received the BCG vaccination. The vaccine aims to stimulate a robust lung immune response through aerosol inhalation, with the goal of eliminating tuberculosis, controlling latent infections, and achieving effective infection prevention.
Clinical Study Objectives
The Phase I clinical study will evaluate the safety and immunogenicity of a single dose of the inhalable tuberculosis booster vaccine in adults aged 18 to 49 in Indonesia. This marks a significant step forward in the development of innovative tuberculosis prevention strategies.-Fineline Info & Tech